Brief: I-Mab, Genexine Report China NMPA Clearance For Phase 2 Glioblastoma Multiforme Clinical Trial

Genexine

21/05/2020 13:32

May 21 (Reuters) - I-Mab  IMAB.O :
    * I-MAB AND GENEXINE ANNOUNCE CHINA NMPA CLEARANCE FOR PHASE
2
CLINICAL TRIAL OF TJ107/HYLEUKIN-7™ IN GLIOBLASTOMA MULTIFORME
    * I-MAB - FINANCIAL TERMS ARE NOT DISCLOSED
    * I-MAB - I-MAB WILL BE MAINLY RESPONSIBLE FOR CONDUCTING
PHASE 2
GBM CLINICAL TRIAL IN CHINA
    * I-MAB - GENEXINE WILL SHARE DEVELOPMENT STRATEGIES, DATA
AND
COSTS FOR SUCCESS OF THIS CLINICAL TRIAL
    * I-MAB - I-MAB AND GENEXINE EXPAND COLLABORATION FOR
DEVELOPMENT
OF TJ107/HYLEUKIN-7™

Source text for Eikon:  ID:nPn8L1S0Ka 
Further company coverage:  IMAB.O 

 ((Reuters.Briefs@thomsonreuters.com;))